KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash & Equivalents (2018 - 2026)

Twist Bioscience has reported Cash & Equivalents over the past 9 years, most recently at $122.7 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 41.69% to $122.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $122.7 million through Mar 2026, down 41.69% year-over-year, with the annual reading at $183.0 million for FY2025, 19.12% down from the prior year.
  • Cash & Equivalents was $122.7 million for Q1 2026 at Twist Bioscience, down from $148.6 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $407.6 million in Q1 2022 and troughed at $122.7 million in Q1 2026.
  • The 5-year median for Cash & Equivalents is $243.3 million (2024), against an average of $261.8 million.
  • Year-over-year, Cash & Equivalents surged 65.26% in 2022 and then plummeted 41.69% in 2026.
  • A 5-year view of Cash & Equivalents shows it stood at $316.7 million in 2022, then dropped by 15.92% to $266.3 million in 2023, then fell by 16.85% to $221.4 million in 2024, then crashed by 32.88% to $148.6 million in 2025, then decreased by 17.43% to $122.7 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Cash & Equivalents are $122.7 million (Q1 2026), $148.6 million (Q4 2025), and $183.0 million (Q3 2025).